Moberg Pharma
11.00 SEK
+3.68 %
Less than 1K followers
MOB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Moberg Pharma
P/E
Median 2019-2025
EV/S
Median 2022-2024
P/B
Median 2020-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 89.37 | 40.23 | 34.57 | 15.47 | 15.20 | 10.17 | 10.27 |
| Shares | 3.3 | 2.9 | 6.7 | 15.1 | 28.4 | 47.9 | 47.0 |
| Market cap | 296.8 | 118.1 | 231.1 | 234.0 | 431.8 | 486.9 | 482.7 |
| Enterprise value | - | 106.3 | 132.4 | 114.5 | 376.0 | 197.8 | - |
| EV/S | - | - | - | 553.4 | - | 20.2 | - |
| EV/EBITDA | - | neg. | neg. | neg. | neg. | neg. | - |
| EV/EBIT | - | neg. | neg. | neg. | neg. | neg. | - |
| P/E | 0.5 | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | - | 0.30 | 0.53 | 0.44 | 0.71 | 0.71 | 0.73 |
| P/S | - | - | - | 1,130.4 | - | 49.6 | 35.7 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | - | 82.3 % | 96.3 % | 94.5 % | 96.2 % | 97.3 % | 97.5 % |
| Gearing ratio | - | 1.9 % | 0.9 % | 1.1 % | 0.8 % | 0.6 % | 0.4 % |